SCHEMBL4454107

SCHEMBL4454107

COc1c(C(C)(C)C)cc(-c2cccc(C3CCN(C(=O)Cn4cc(C)nc4C)CC3)n2)cc1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 3/20 0.39
UBE2M P61081 2/20 0.37
DCUN1D1 Q96GG9 2/20 0.37
HTR1A P08908 3/20 0.36
DRD2 P14416 3/20 0.36
DRD4 P21917 3/20 0.36
KCNH2 Q12809 2/20 0.36
FFAR4 Q5NUL3 3/20 0.35
LMNA P02545 2/20 0.35
GRIN2B Q13224 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
POLB P06746 1/20 0.33
GRM5 P41594 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4463529 0.85 CXCR3 (0.42) IRAK4HTR1ADRD2DRD4KCNH2
SCHEMBL3581627 0.84 IRAK4 (0.33) IRAK4UBE2MDCUN1D1KCNH2LMNA
SCHEMBL4461312 0.81 CXCR3 (0.47) KCNH2
SCHEMBL13031134 0.81 PTGS2 (0.35) LMNAGRIN2B
SCHEMBL4458994 0.79 HTT (0.48) KDM4EALDH1A1
SCHEMBL3584110 0.76 IRAK4 (0.34) IRAK4GRIN2BPOLB
SCHEMBL3590320 0.76 IRAK4 (0.33) IRAK4KCNH2LMNAGRIN2BPSEN1
SCHEMBL3583149 0.76 IRAK4 (0.32) IRAK4UBE2MDCUN1D1LMNAGRIN2B
SCHEMBL13031155 0.74 PTGS2 (0.33) LMNAGRIN2BPOLB
SCHEMBL13031258 0.74 GRIN2B (0.35) GRIN2BPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
WO-2007100610-A2 PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators CXCR3, CXCR1, CXCR5 IRAK4 492/4885UBE2M 4733/4885DCUN1D1 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.